AMLX stock news · Amylyx Pharma
Get alerts for AMLX
Follow Amylyx Pharma (AMLX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AMLXAmylyx Pharma shared details from its earnings call for the second quarter of 2026.
NeutralAmylyx reported funds to support operations into 2028, rising costs, and upcoming Avexitide trial results. With those results still unknown, the update does not change its outlook.
Amylyx Pharmaceuticals, Inc. secures a significant definitive agreement (AMLX).
NeutralAmylyx Pharmaceuticals has filed a Form 8-K indicating its entry into a material definitive agreement, which is likely to have a positive impact on its strategic direction and financial outlook. This development is crucial as it may open new avenues for collaboration or funding, enhancing investor confidence.
Today, investors are focusing on five stocks: Profusa, Baidu, Amylyx Pharmaceuticals, FreeCast, and Klarna Group.
Good for AMLXAmylyx's stock increased 63.84% following the release of positive topline data, indicating strong investor interest.
Positive Q2 results from Duos Technologies contribute to a rise in stock prices alongside Amylyx Pharmaceuticals, Weave Communications, and other major companies on Tuesday.
Good for AMLXAmylyx Pharmaceuticals shares surged after announcing positive results from its Phase 3 trial.
Amylyx Pharmaceuticals advances toward possibly providing the inaugural therapy for low sugar levels associated with weight loss surgery.
Good for AMLXAmylyx Pharmaceuticals' stock is trading higher following the announcement of positive topline data from its Phase 3 LUCIDITY trial for avexitide, which demonstrated significant efficacy in reducing hypoglycemic episodes in patients post-bariatric surgery. This breakthrough could lead to FDA approval and a commercial launch, enhancing the company's market position.
Amylyx Pharmaceuticals' shares jump in after-hours trading due to anticipation surrounding avexitide Phase 3 trial outcomes.
NeutralAmylyx Pharmaceuticals' stock surged after-hours as investors anticipate the upcoming Phase 3 trial results for avexitide, a potential treatment for post-bariatric hypoglycemia. The results, set to be announced soon, could validate the drug's efficacy and safety, leading to a significant market reaction.